Antiparasitic pyrrolopyrimidines

抗寄生虫吡咯并嘧啶类

• 批准号: G0901426/1
• 负责人: Colin Suckling
• 金额: $ 85.75万
• 依托单位: University of Strathclyde
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2010
• 资助国家: 英国
• 起止时间: 2010 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G0901426%2F1
• 关键词: Antiparasitic; pyrrolopyrimidines

Parasitic diseases, including malaria, leishmaniasis, and trypanosomiasis are amongst the most prevalent diseases world wide collectively with the poorest availability of effective drugs. Human African trypanosomiasis (HAT) has been reported to have a greater morbidity and mortality than HIV/AIDS in some locations. Parasitic disease is difficult to treat because the parasites become closely connected with the living host and it is therefore difficult to find drugs that attack only the parasite. Available drugs are few and are also toxic to humans. In laboratory experiments, we have shown that novel compounds designed and prepared in at the University of Strathclyde and University of Dundee are potentially able to fill the gap in drug availability. Our project is to optimise the effectiveness of our compounds to provide candidate drugs for full clinical development.

包括疟疾、利什曼病和锥虫病在内的寄生虫病是世界范围内最流行的疾病之一，有效药物的可获得性最差。据报告，非洲人类锥虫病(HAT)在某些地区的发病率和死亡率高于艾滋病毒/艾滋病。寄生虫病很难治疗，因为寄生虫与活的宿主紧密相连，因此很难找到只攻击寄生虫的药物。可用的药物很少，而且对人类也是有毒的。在实验室实验中，我们已经表明，斯特拉斯克莱德大学和邓迪大学设计和制备的新型化合物有可能填补药物供应方面的空白。我们的项目是优化我们化合物的有效性，为全面的临床开发提供候选药物。